Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review

Hepatic dysfunction, in the absence of liver metastases, occurs in 10–15% of renal cell carcinoma (RCC) patients, while immune hepatitis due to anti-CTLA4 and anti-PD1 administration affects about 3–9% and 0.7–1.8% of treated patients, respectively. Liver toxicity following combination therapy (anti...

Full description

Bibliographic Details
Main Authors: Nerina Denaro, Ornella Garrone, Marcella Occelli, Elena Fea, Cristina Granetto, Marco Carlo Merlano, Gianmauro Numico
Format: Article
Language:English
Published: SMC MEDIA SRL 2021-06-01
Series:European Journal of Case Reports in Internal Medicine
Subjects:
hepatitis
hepatic failure
immunotherapy
renal carcinoma
Online Access:https://www.ejcrim.com/index.php/EJCRIM/article/view/2639

Internet

https://www.ejcrim.com/index.php/EJCRIM/article/view/2639

Similar Items